Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients
<b>Background/Objectives:</b> Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, and its prognostic role has never been explored in coronavirus disease 2019 (COVID-19). We compared the M2BPGi level simultaneously with age, severe/critical disease...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/7/937 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849738688912687104 |
|---|---|
| author | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee |
| author_facet | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee |
| author_sort | Mikyoung Park |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, and its prognostic role has never been explored in coronavirus disease 2019 (COVID-19). We compared the M2BPGi level simultaneously with age, severe/critical disease, the sequential organ failure assessment (SOFA) score, and the National Early Warning Score 2 (NEWS2) in a total of 53 hospitalized patients with COVID-19 (mild/moderate [<i>n</i> = 15] and severe/critical [<i>n</i> = 38]). <b>Methods:</b> M2BPGi levels were measured using the HISCL M2BPGi assay (Sysmex, Kobe, Japan) in an HISCL-5000 analyzer (Sysmex), and clinical outcomes were analyzed according to M2BPGi and the clinical variables, using the receiver operating characteristic (ROC) curve, Kaplan–Meier survival, and Cox proportional hazards regression analyses. <b>Results:</b> M2BPGi levels differed significantly according to disease severity, 30-day mortality, and 60-day mortality (<i>p</i> = 0.045, 0.011, and 0.002, respectively). In the ROC curve analysis, the M2BPGi, age, SOFA score, and NEWS2, except for severe/critical disease, significantly predicted clinical outcomes (all <i>p</i> < 0.01). In the survival analysis, the hazard ratios of M2BPGi added to each clinical variable were higher than that of each clinical variable alone, and M2BPGi was the only independent prognostic factor for the mortality. <b>Conclusions:</b> This study demonstrated that M2BPGi may be a useful biomarker for assessing disease severity and clinical outcomes in hospitalized COVID-19 patients. Combined with conventional clinical assessment, M2BPGi would provide objective and valuable information for prognosis prediction in these critically ill patients. Further studies are warranted to extend its utility in other clinical settings. |
| format | Article |
| id | doaj-art-3bb61f55c7a1426083f3979f8c9f2aca |
| institution | DOAJ |
| issn | 2075-4418 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-3bb61f55c7a1426083f3979f8c9f2aca2025-08-20T03:06:29ZengMDPI AGDiagnostics2075-44182025-04-0115793710.3390/diagnostics15070937Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 PatientsMikyoung Park0Mina Hur1Hanah Kim2Chae Hoon Lee3Jong Ho Lee4Hyung Woo Kim5Minjeong Nam6Seungho Lee7Department of Laboratory Medicine, Ajou University School of Medicine, Suwon 16499, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of KoreaDepartment of Laboratory Medicine, Yeongnam University College of Medicine, Daegu 42415, Republic of KoreaDepartment of Laboratory Medicine, Yeongnam University College of Medicine, Daegu 42415, Republic of KoreaDepartment of Laboratory Medicine, CHA Gumi Medical Center, CHA University, Gumi 39295, Republic of KoreaDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul 02841, Republic of KoreaDepartment of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, Republic of Korea<b>Background/Objectives:</b> Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, and its prognostic role has never been explored in coronavirus disease 2019 (COVID-19). We compared the M2BPGi level simultaneously with age, severe/critical disease, the sequential organ failure assessment (SOFA) score, and the National Early Warning Score 2 (NEWS2) in a total of 53 hospitalized patients with COVID-19 (mild/moderate [<i>n</i> = 15] and severe/critical [<i>n</i> = 38]). <b>Methods:</b> M2BPGi levels were measured using the HISCL M2BPGi assay (Sysmex, Kobe, Japan) in an HISCL-5000 analyzer (Sysmex), and clinical outcomes were analyzed according to M2BPGi and the clinical variables, using the receiver operating characteristic (ROC) curve, Kaplan–Meier survival, and Cox proportional hazards regression analyses. <b>Results:</b> M2BPGi levels differed significantly according to disease severity, 30-day mortality, and 60-day mortality (<i>p</i> = 0.045, 0.011, and 0.002, respectively). In the ROC curve analysis, the M2BPGi, age, SOFA score, and NEWS2, except for severe/critical disease, significantly predicted clinical outcomes (all <i>p</i> < 0.01). In the survival analysis, the hazard ratios of M2BPGi added to each clinical variable were higher than that of each clinical variable alone, and M2BPGi was the only independent prognostic factor for the mortality. <b>Conclusions:</b> This study demonstrated that M2BPGi may be a useful biomarker for assessing disease severity and clinical outcomes in hospitalized COVID-19 patients. Combined with conventional clinical assessment, M2BPGi would provide objective and valuable information for prognosis prediction in these critically ill patients. Further studies are warranted to extend its utility in other clinical settings.https://www.mdpi.com/2075-4418/15/7/937M2BPGiCOVID-19severityclinical outcomeSOFANEWS2 |
| spellingShingle | Mikyoung Park Mina Hur Hanah Kim Chae Hoon Lee Jong Ho Lee Hyung Woo Kim Minjeong Nam Seungho Lee Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients Diagnostics M2BPGi COVID-19 severity clinical outcome SOFA NEWS2 |
| title | Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_full | Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_fullStr | Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_full_unstemmed | Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_short | Novel Usefulness of M2BPGi for Predicting Severity and Clinical Outcomes in Hospitalized COVID-19 Patients |
| title_sort | novel usefulness of m2bpgi for predicting severity and clinical outcomes in hospitalized covid 19 patients |
| topic | M2BPGi COVID-19 severity clinical outcome SOFA NEWS2 |
| url | https://www.mdpi.com/2075-4418/15/7/937 |
| work_keys_str_mv | AT mikyoungpark novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT minahur novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT hanahkim novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT chaehoonlee novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT jongholee novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT hyungwookim novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT minjeongnam novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients AT seungholee novelusefulnessofm2bpgiforpredictingseverityandclinicaloutcomesinhospitalizedcovid19patients |